BCMA-CD19 CCAR T Cell Treatment of Refractory Immune Thrombocytopenia Associated with Autoimmune Diseases

NCT06787989 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Refractory Immune Cytopenia

Interventions

BIOLOGICAL: BCMA-CD19 cCAR T cells

Sponsor

iCell Gene Therapeutics

Collaborators

[object Object]